Home › Aplastic Anemia › Washington › Seattle
Aplastic Anemia clinical trials in Seattle, WA
4 studies for Aplastic Anemia are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
RecruitingPhase 1/2
- Dren Investigational Site, Seattle
The HOPE Biobank Resource (BMT CTN 2402 HOPE)
RecruitingObservational studyHealthy volunteers welcome
- Fred Hutchinson Cancer Center, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Fred Hutchinson Cancer Research Center, Seattle
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
About Aplastic Anemia
Aplastic anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make enough new blood cells. Read more on the causes.
More about Aplastic Anemia on MedlinePlus
Aplastic Anemia trials in other cities
- Washington, DC8 studies
- Baldwin Park, CA7 studies
- New York City, NY5 studies
- Atlanta, GA5 studies
- Philadelphia, PA4 studies
- Milwaukee, WI4 studies
- St. Louis, MO4 studies
- Houston, TX4 studies
- Nashville, TN4 studies
- Columbus, OH4 studies
- Durham, NC4 studies
- Memphis, TN3 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer55 studies
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.